Autopsy report · NCT01193881
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Cause of deathNo reason given
Life of this trial
- Ran for about 5 years before it stopped.
- 16 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer
- Interventions
- Erlotinib Hydrochloride; Gamma-Secretase Inhibitor RO4929097; Laboratory Biomarker Analysis; Pharmacological Study
- Participants
- 16
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.